Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges

Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicina (Kaunas, Lithuania) Jg. 59; H. 10; S. 1886
Hauptverfasser:	Wen, Xiaofen, Coradduzza, Donatella, Shen, Jiaxin, Scanu, Antonio Mario, Muroni, Maria Rosaria, Massidda, Matteo, Rallo, Vincenzo, Carru, Ciriaco, Angius, Andrea, De Miglio, Maria Rosaria
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 01.10.2023 MDPI
Schlagworte:	Biomarkers, Tumor - genetics Biopsy Cancer Cancer therapies Care and treatment Chemotherapy Clinical medicine Clinical Relevance Colorectal cancer colorectal cancer (CRC) Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Development and progression Diagnosis Disease Humans Japan Metastasis Minimal Residual Disease (MRD) MRD clinical application in CRC MRD techniques Neoplasm, Residual - diagnosis Oncology Oncology, Experimental Patients Review Serology Tumors Japan colorectal cancer (CRC) Minimal Residual Disease (MRD) MRD techniques MRD clinical application in CRC
ISSN:	1648-9144, 1010-660X, 1648-9144
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.
AbstractList	Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC. Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.
Audience	Academic
Author	Wen, Xiaofen Massidda, Matteo Rallo, Vincenzo Shen, Jiaxin Carru, Ciriaco Muroni, Maria Rosaria Coradduzza, Donatella De Miglio, Maria Rosaria Scanu, Antonio Mario Angius, Andrea
AuthorAffiliation	3 Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China 2 Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China 4 Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy; scanu@uniss.it (A.M.S.); mrmuroni@uniss.it (M.R.M.); mmassidda@uniss.it (M.M.) 5 Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, CNR, Cittadella Universitaria di Cagliari, Monserrato, 09042 Cagliari, Italy; vincenzo.rallo@irgb.cnr.it (V.R.); andrea.angius@irgb.cnr.it (A.A.) 1 Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; x.wen@studenti.uniss.it (X.W.); dcoradduzza@uniss.it (D.C.); j.shen@studenti.uniss.it (J.S.); carru@uniss.it (C.C.)
AuthorAffiliation_xml	– name: 1 Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; x.wen@studenti.uniss.it (X.W.); dcoradduzza@uniss.it (D.C.); j.shen@studenti.uniss.it (J.S.); carru@uniss.it (C.C.) – name: 3 Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China – name: 4 Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy; scanu@uniss.it (A.M.S.); mrmuroni@uniss.it (M.R.M.); mmassidda@uniss.it (M.M.) – name: 5 Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, CNR, Cittadella Universitaria di Cagliari, Monserrato, 09042 Cagliari, Italy; vincenzo.rallo@irgb.cnr.it (V.R.); andrea.angius@irgb.cnr.it (A.A.) – name: 2 Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China
Author_xml	– sequence: 1 givenname: Xiaofen surname: Wen fullname: Wen, Xiaofen – sequence: 2 givenname: Donatella orcidid: 0000-0002-8978-0490 surname: Coradduzza fullname: Coradduzza, Donatella – sequence: 3 givenname: Jiaxin orcidid: 0000-0003-0146-8863 surname: Shen fullname: Shen, Jiaxin – sequence: 4 givenname: Antonio Mario orcidid: 0000-0001-7878-1167 surname: Scanu fullname: Scanu, Antonio Mario – sequence: 5 givenname: Maria Rosaria surname: Muroni fullname: Muroni, Maria Rosaria – sequence: 6 givenname: Matteo orcidid: 0000-0002-5246-5585 surname: Massidda fullname: Massidda, Matteo – sequence: 7 givenname: Vincenzo orcidid: 0000-0002-8938-5650 surname: Rallo fullname: Rallo, Vincenzo – sequence: 8 givenname: Ciriaco orcidid: 0000-0002-6985-4907 surname: Carru fullname: Carru, Ciriaco – sequence: 9 givenname: Andrea orcidid: 0000-0003-2596-6461 surname: Angius fullname: Angius, Andrea – sequence: 10 givenname: Maria Rosaria orcidid: 0000-0002-9393-3234 surname: De Miglio fullname: De Miglio, Maria Rosaria
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/37893604$$D View this record in MEDLINE/PubMed
BookMark	eNp1kttrFDEUhwep2Iu--yQDvviyNZfJJOOLLOtlCxVF-h7OJCfbLLNJTWYL-teb6bbaXZQhTEi-84Xf4ZxWRyEGrKqXlJxz3pG3G7Te-ACio4Qq1T6pTmjbqFlHm-bo0f64Os15TQhnQrJn1TGXquMtaU6qsIQUMGcfVvUXH_wGhvo7Zm-3ZfPBZ4SMNeQa6m9pemyMqXZlLeIQE5qxUAsIBtO7AsSNvxMtY_K_Ysj1fONtHuvFNQwDhhXm59VTB0PGF_f_s-rq08erxXJ2-fXzxWJ-OTNCqHHmetfLjgvZ2h45Zz0Y4rhsJXWOcyRUGGWx51IwSyxBRZy15QKEJNBQflZd7LQ2wlrfpBIr_dQRvL47iGmlIY3eDKhByY4pROl60ziuwHCrhMOWyJYxYYvr_c51s-1Lvw2GMcGwJ92_Cf5ar-KtpqQlStGuGN7cG1L8scU86tIng8MAAeM2a6ZUiSqabkJfH6DruE2htGqiWEtoQ9lfagUlgQ8ulofNJNVzKRnpOkJJoc7_QZXP4sabMkjOl_O9glePk_6J-DAtBWh3gEkx54ROGz_C6OMU3A8lsZ7GUh-OZSkkB4UP7v-W_AYwzOcB
CitedBy_id	crossref_primary_10_3389_fonc_2024_1303335 crossref_primary_10_3390_jcm13072102 crossref_primary_10_3390_medicina59122124
Cites_doi	10.3390/biology12040558 10.1016/S1470-2045(21)00079-6 10.1126/scitranslmed.aan2415 10.1038/s41576-018-0071-5 10.3389/fonc.2023.1103797 10.7150/ijbs.64077 10.1016/j.ijrobp.2018.09.016 10.1126/scitranslmed.aaf6219 10.1093/annonc/mdy526 10.4174/astr.2023.104.5.281 10.1001/jamaoncol.2019.0512 10.1016/S1470-2045(19)30691-6 10.1200/JCO.2004.09.059 10.3748/wjg.v20.i43.16178 10.1038/s41416-021-01591-8 10.1001/jamaoncol.2023.0425 10.1001/jama.1993.03510080047030 10.1200/JCO.21.02615 10.1158/1078-0432.CCR-17-0510 10.1126/scitranslmed.aay2574 10.1136/gutjnl-2014-308859 10.3390/ijms241210230 10.21147/j.issn.1000-9604.2021.03.02 10.1093/annonc/mdv177 10.1136/gutjnl-2022-327736 10.6004/jnccn.2021.0012 10.1038/s41591-022-02115-4 10.5306/wjco.v11.i10.761 10.1158/1078-0432.CCR-19-1209 10.1016/j.ebiom.2022.103945 10.1158/1078-0432.CCR-21-2404 10.1038/s41416-022-01769-8 10.1245/s10434-022-12641-7 10.3322/caac.21731 10.1200/JCO.2008.19.5362 10.1056/NEJMoa032709 10.1038/s41571-021-00495-z 10.1007/s00432-022-04301-w 10.1245/s10434-023-13604-2 10.3390/ijms23126836 10.1001/jamaoncol.2019.0528 10.1007/s11845-018-1951-6 10.1038/nrclinonc.2016.171 10.1038/s41571-020-0392-0 10.1016/j.ejca.2021.09.004 10.14740/gr1167 10.1056/NEJMoa1713709 10.3390/ijms24010101 10.1200/JCO.2023.41.16_suppl.3521 10.1371/journal.pmed.1003620 10.1200/PO.21.00535 10.1200/JCO.2020.38.4_suppl.180 10.3748/wjg.v13.i40.5357 10.3390/cancers13020346 10.1016/j.annonc.2022.05.520 10.3390/ijms231911529 10.1001/jama.2021.0106 10.1158/1078-0432.CCR-21-0410 10.1056/NEJMoa2200075 10.1155/2017/2195361 10.1200/JCO.2023.41.4_suppl.227 10.1158/1078-0432.CCR-21-0271 10.1200/JCO.2018.36.4_suppl.661 10.1200/JCO.2023.41.4_suppl.5 10.3390/biom12040514 10.20944/preprints202301.0302.v1 10.1186/s13045-021-01089-z 10.1200/jco.2014.32.3_suppl.654 10.1093/clinchem/hvaa223 10.1200/JCO.2023.41.4_suppl.TPS284
ContentType	Journal Article
Copyright	COPYRIGHT 2023 MDPI AG 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 by the authors. 2023
Copyright_xml	– notice: COPYRIGHT 2023 MDPI AG – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 by the authors. 2023
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA
DOI	10.3390/medicina59101886
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE MEDLINE - Academic CrossRef
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1648-9144
ExternalDocumentID	oai_doaj_org_article_a87928ee7fbc4f38ac3d85fe6076225d PMC10608819 A772099010 37893604 10_3390_medicina59101886
Genre	Journal Article Review
GeographicLocations	Japan
GeographicLocations_xml	– name: Japan
GrantInformation_xml	– fundername: Fondazione di Sardegna grantid: 2023 – fundername: Fondazione di Sardegna
GroupedDBID	0R~ 29M 2WC 4.4 457 53G 5GY 5VS 7X7 8FI 8FJ AADQD AAEDT AAFWJ AAIKJ AAYXX ABMAC ABUWG ACGFS ADBBV ADEZE AFFHD AFKRA AFPKN AFZYC AGHFR AHDRD ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CITATION EMOBN F5P FDB FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR ITC KQ8 MODMG O9- OK1 OVT PGMZT PHGZM PHGZT PIMPY RPM UKHRP XSB ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM
ID	FETCH-LOGICAL-c558t-fbfb793576dbe332bac0f37671ff33e015c8deb3752d0d0e80fdd33ea570a413
IEDL.DBID	DOA
ISICitedReferencesCount	3
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001089806800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1648-9144 1010-660X
IngestDate	Fri Oct 03 12:51:44 EDT 2025 Tue Nov 04 02:06:12 EST 2025 Sun Nov 09 14:19:07 EST 2025 Tue Oct 07 07:00:47 EDT 2025 Tue Nov 11 11:12:14 EST 2025 Tue Nov 04 18:42:39 EST 2025 Mon Jul 21 06:17:39 EDT 2025 Sat Nov 29 07:14:02 EST 2025 Tue Nov 18 21:47:17 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Keywords	colorectal cancer (CRC) Minimal Residual Disease (MRD) MRD techniques MRD clinical application in CRC
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c558t-fbfb793576dbe332bac0f37671ff33e015c8deb3752d0d0e80fdd33ea570a413
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 These authors contributed equally to this work.
ORCID	0000-0003-0146-8863 0000-0002-8978-0490 0000-0002-9393-3234 0000-0001-7878-1167 0000-0002-5246-5585 0000-0002-8938-5650 0000-0002-6985-4907 0000-0003-2596-6461
OpenAccessLink	https://doaj.org/article/a87928ee7fbc4f38ac3d85fe6076225d
PMID	37893604
PQID	2882601412
PQPubID	5046879
ParticipantIDs	doaj_primary_oai_doaj_org_article_a87928ee7fbc4f38ac3d85fe6076225d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10608819 proquest_miscellaneous_2883575499 proquest_journals_2882601412 gale_infotracmisc_A772099010 gale_infotracacademiconefile_A772099010 pubmed_primary_37893604 crossref_citationtrail_10_3390_medicina59101886 crossref_primary_10_3390_medicina59101886
PublicationCentury	2000
PublicationDate	2023-10-01
PublicationDateYYYYMMDD	2023-10-01
PublicationDate_xml	– month: 10 year: 2023 text: 2023-10-01 day: 01
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	Medicina (Kaunas, Lithuania)
PublicationTitleAlternate	Medicina (Kaunas)
PublicationYear	2023
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	Shitara (ref_52) 2019; 30 Hauptman (ref_7) 2017; 2017 Sargent (ref_29) 2009; 27 Reinert (ref_43) 2017; 23 ref_10 Henriksen (ref_46) 2022; 28 Wang (ref_15) 2019; 5 Bendell (ref_68) 2020; 26 Pascual (ref_19) 2022; 33 Smyth (ref_3) 2019; 188 Malla (ref_12) 2022; 40 Bylsma (ref_70) 2020; 13 Biller (ref_74) 2021; 325 Martin (ref_57) 2020; 11 Boni (ref_26) 2004; 350 Aarons (ref_9) 2014; 20 Chung (ref_58) 2019; 103 Henry (ref_54) 2020; 38 Manca (ref_61) 2022; 126 Taieb (ref_39) 2021; 27 Miller (ref_31) 2022; 72 Ayez (ref_64) 2015; 41 Lueong (ref_67) 2020; 66 Vitiello (ref_73) 2021; 18 Benson (ref_17) 2021; 19 ref_24 ref_23 ref_22 ref_21 Mo (ref_48) 2023; 9 ref_27 Johnston (ref_53) 2023; 13 Parikh (ref_55) 2021; 27 Dasari (ref_16) 2020; 17 Tie (ref_36) 2022; 386 Tie (ref_44) 2016; 8 Conroy (ref_69) 2021; 22 Wang (ref_65) 2023; 30 Raghav (ref_71) 2018; 36 Tie (ref_66) 2015; 26 Dabak (ref_8) 2007; 13 Reinert (ref_45) 2016; 65 Punt (ref_33) 2017; 14 Bando (ref_60) 2022; 6 Phallen (ref_20) 2017; 9 Gill (ref_28) 2004; 22 Oki (ref_47) 2023; 41 Kotani (ref_35) 2023; 29 Storandt (ref_14) 2023; 41 Benhaim (ref_40) 2021; 159 Mauri (ref_51) 2022; 127 Angius (ref_11) 2023; 149 Reinert (ref_42) 2019; 5 Grothey (ref_37) 2018; 378 Salem (ref_50) 2023; 41 Cohen (ref_56) 2023; 41 Dong (ref_18) 2021; 33 Custers (ref_38) 2016; 24 Dawood (ref_13) 2023; 30 Fan (ref_25) 2021; 17 Heitzer (ref_59) 2019; 20 Chen (ref_41) 2021; 14 Mitchell (ref_62) 2014; 32 Figueredo (ref_30) 2008; 2008 ref_2 ref_49 Doebele (ref_72) 2020; 21 Morgan (ref_1) 2023; 72 Ooft (ref_34) 2019; 11 Moertel (ref_63) 1993; 270 Paik (ref_32) 2023; 104 ref_5 ref_4 ref_6
References_xml	– ident: ref_4 doi: 10.3390/biology12040558 – volume: 24 start-page: 555 year: 2016 ident: ref_38 article-title: Fear of cancer recurrence in colorectal cancer survivors publication-title: Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer – volume: 22 start-page: 702 year: 2021 ident: ref_69 article-title: Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00079-6 – volume: 9 start-page: eaan2415 year: 2017 ident: ref_20 article-title: Direct detection of early-stage cancers using circulating tumor DNA publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aan2415 – volume: 20 start-page: 71 year: 2019 ident: ref_59 article-title: Current and future perspectives of liquid biopsies in genomics-driven oncology publication-title: Nat. Rev. Genet. doi: 10.1038/s41576-018-0071-5 – volume: 13 start-page: 1103797 year: 2023 ident: ref_53 article-title: Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? publication-title: Front. Oncol doi: 10.3389/fonc.2023.1103797 – volume: 17 start-page: 3837 year: 2021 ident: ref_25 article-title: Immunotherapy in colorectal cancer: Current achievements and future perspective publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.64077 – volume: 103 start-page: 438 year: 2019 ident: ref_58 article-title: Adjuvant Chemotherapy in Rectal Cancer Patients Treated with Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2018.09.016 – volume: 8 start-page: 346ra92 year: 2016 ident: ref_44 article-title: Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aaf6219 – volume: 30 start-page: 259 year: 2019 ident: ref_52 article-title: REVERCE: A randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdy526 – volume: 104 start-page: 281 year: 2023 ident: ref_32 article-title: Risk factors of recurrence in TNM stage I colorectal cancer publication-title: Ann. Surg. Treat. Res. doi: 10.4174/astr.2023.104.5.281 – volume: 5 start-page: 1118 year: 2019 ident: ref_15 article-title: Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.0512 – volume: 21 start-page: 271 year: 2020 ident: ref_72 article-title: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30691-6 – volume: 22 start-page: 1797 year: 2004 ident: ref_28 article-title: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2004.09.059 – volume: 20 start-page: 16178 year: 2014 ident: ref_9 article-title: Management of malignant colon polyps: Current status and controversies publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v20.i43.16178 – volume: 126 start-page: 449 year: 2022 ident: ref_61 article-title: Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: A translational objective of the Valentino study publication-title: Br. J. Cancer doi: 10.1038/s41416-021-01591-8 – volume: 9 start-page: 770 year: 2023 ident: ref_48 article-title: Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2023.0425 – volume: 270 start-page: 943 year: 1993 ident: ref_63 article-title: An Evaluation of the Carcinoembryonic Antigen (CEA) Test for Monitoring Patients with Resected Colon Cancer publication-title: JAMA doi: 10.1001/jama.1993.03510080047030 – volume: 41 start-page: 859 year: 2015 ident: ref_64 article-title: The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator publication-title: Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. – volume: 40 start-page: 2846 year: 2022 ident: ref_12 article-title: Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.21.02615 – volume: 23 start-page: 5437 year: 2017 ident: ref_43 article-title: Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-17-0510 – volume: 11 start-page: eaay2574 year: 2019 ident: ref_34 article-title: Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aay2574 – volume: 2008 start-page: Cd005390 year: 2008 ident: ref_30 article-title: Adjuvant therapy for completely resected stage II colon cancer publication-title: Cochrane Database Syst. Rev. – ident: ref_27 – volume: 65 start-page: 625 year: 2016 ident: ref_45 article-title: Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery publication-title: Gut doi: 10.1136/gutjnl-2014-308859 – ident: ref_21 doi: 10.3390/ijms241210230 – volume: 33 start-page: 302 year: 2021 ident: ref_18 article-title: Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020 publication-title: Chin. J. Cancer Res. doi: 10.21147/j.issn.1000-9604.2021.03.02 – volume: 26 start-page: 1715 year: 2015 ident: ref_66 article-title: Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdv177 – volume: 72 start-page: 338 year: 2023 ident: ref_1 article-title: Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN publication-title: Gut doi: 10.1136/gutjnl-2022-327736 – volume: 19 start-page: 329 year: 2021 ident: ref_17 article-title: Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2021.0012 – volume: 29 start-page: 127 year: 2023 ident: ref_35 article-title: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer publication-title: Nat. Med. doi: 10.1038/s41591-022-02115-4 – volume: 11 start-page: 761 year: 2020 ident: ref_57 article-title: Colorectal liver metastases: Current management and future perspectives publication-title: World J. Clin. Oncol. doi: 10.5306/wjco.v11.i10.761 – volume: 26 start-page: 4010 year: 2020 ident: ref_68 article-title: Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-19-1209 – ident: ref_24 doi: 10.1016/j.ebiom.2022.103945 – volume: 28 start-page: 507 year: 2022 ident: ref_46 article-title: Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-21-2404 – volume: 127 start-page: 394 year: 2022 ident: ref_51 article-title: Liquid biopsies to monitor and direct cancer treatment in colorectal cancer publication-title: Br. J. Cancer doi: 10.1038/s41416-022-01769-8 – volume: 30 start-page: 259 year: 2023 ident: ref_13 article-title: Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-022-12641-7 – volume: 72 start-page: 409 year: 2022 ident: ref_31 article-title: Cancer treatment and survivorship statistics, 2022 publication-title: CA A Cancer J. Clin. doi: 10.3322/caac.21731 – volume: 27 start-page: 872 year: 2009 ident: ref_29 article-title: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2008.19.5362 – volume: 350 start-page: 2343 year: 2004 ident: ref_26 article-title: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa032709 – volume: 18 start-page: 506 year: 2021 ident: ref_73 article-title: Precision oncology in metastatic colorectal cancer—from biology to medicine publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-021-00495-z – volume: 149 start-page: 3951 year: 2023 ident: ref_11 article-title: Deciphering clinical significance of BCL11A isoforms and protein expression roles in triple-negative breast cancer subtype publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-022-04301-w – volume: 30 start-page: 5252 year: 2023 ident: ref_65 article-title: Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-023-13604-2 – ident: ref_10 doi: 10.3390/ijms23126836 – volume: 5 start-page: 1124 year: 2019 ident: ref_42 article-title: Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal Cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.0528 – volume: 188 start-page: 1079 year: 2019 ident: ref_3 article-title: Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure publication-title: Ir. J. Med. Sci. doi: 10.1007/s11845-018-1951-6 – volume: 14 start-page: 235 year: 2017 ident: ref_33 article-title: From tumour heterogeneity to advances in precision treatment of colorectal cancer publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2016.171 – volume: 17 start-page: 757 year: 2020 ident: ref_16 article-title: ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal-Anal Task Forces whitepaper publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0392-0 – volume: 159 start-page: 24 year: 2021 ident: ref_40 article-title: Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: Multicentric, prospective cohort study (ALGECOLS) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2021.09.004 – volume: 13 start-page: 184 year: 2020 ident: ref_70 article-title: A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer publication-title: Gastroenterol. Res. doi: 10.14740/gr1167 – volume: 378 start-page: 1177 year: 2018 ident: ref_37 article-title: Duration of Adjuvant Chemotherapy for Stage III Colon Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1713709 – ident: ref_2 doi: 10.3390/ijms24010101 – volume: 41 start-page: 3521 year: 2023 ident: ref_47 article-title: Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2023.41.16_suppl.3521 – ident: ref_23 doi: 10.1371/journal.pmed.1003620 – volume: 6 start-page: e2100535 year: 2022 ident: ref_60 article-title: Effects of Metastatic Sites on Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer publication-title: JCO Precis. Oncol. doi: 10.1200/PO.21.00535 – volume: 38 start-page: 180 year: 2020 ident: ref_54 article-title: NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.4_suppl.180 – volume: 13 start-page: 5357 year: 2007 ident: ref_8 article-title: Type 2 diabetes mellitus and CA 19-9 levels publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v13.i40.5357 – ident: ref_49 doi: 10.3390/cancers13020346 – volume: 33 start-page: 750 year: 2022 ident: ref_19 article-title: ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2022.05.520 – ident: ref_22 doi: 10.3390/ijms231911529 – volume: 325 start-page: 669 year: 2021 ident: ref_74 article-title: Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review publication-title: JAMA doi: 10.1001/jama.2021.0106 – volume: 27 start-page: 5586 year: 2021 ident: ref_55 article-title: Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-21-0410 – volume: 386 start-page: 2261 year: 2022 ident: ref_36 article-title: Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2200075 – volume: 2017 start-page: 2195361 year: 2017 ident: ref_7 article-title: Colorectal Cancer Blood-Based Biomarkers publication-title: Gastroenterol. Res. Pract. doi: 10.1155/2017/2195361 – volume: 41 start-page: 227 year: 2023 ident: ref_14 article-title: A retrospective study of circulating tumor DNA for minimal residual disease detection in the management of colorectal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2023.41.4_suppl.227 – volume: 27 start-page: 5638 year: 2021 ident: ref_39 article-title: Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-21-0271 – volume: 36 start-page: 661 year: 2018 ident: ref_71 article-title: Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.4_suppl.661 – volume: 41 start-page: 5 year: 2023 ident: ref_56 article-title: Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2023.41.4_suppl.5 – ident: ref_5 doi: 10.3390/biom12040514 – ident: ref_6 doi: 10.20944/preprints202301.0302.v1 – volume: 14 start-page: 80 year: 2021 ident: ref_41 article-title: Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-021-01089-z – volume: 32 start-page: 654 year: 2014 ident: ref_62 article-title: Transient increase in serum CEA while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.3_suppl.654 – volume: 66 start-page: 1510 year: 2020 ident: ref_67 article-title: Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial publication-title: Clin. Chem. doi: 10.1093/clinchem/hvaa223 – volume: 41 start-page: TPS284 year: 2023 ident: ref_50 article-title: NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2023.41.4_suppl.TPS284
SSID	ssj0032572
Score	2.3155005
SecondaryResourceType	review_article
Snippet	Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method...
SourceID	doaj pubmedcentral proquest gale pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	1886
SubjectTerms	Biomarkers, Tumor - genetics Biopsy Cancer Cancer therapies Care and treatment Chemotherapy Clinical medicine Clinical Relevance Colorectal cancer colorectal cancer (CRC) Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Development and progression Diagnosis Disease Humans Japan Metastasis Minimal Residual Disease (MRD) MRD clinical application in CRC MRD techniques Neoplasm, Residual - diagnosis Oncology Oncology, Experimental Patients Review Serology Tumors
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQYgL70egICMhIQ7ROvEmcbigZaHaS6sK9bC3yM8SiSYl2XLg1zOTeJcNSL1wjceRHX-emS9jzwC8tQm6EYlJYpdwjQQll7E2BpWhVNw4mygt_VBsojg5ket1eRp-uPXhWOVWJw6K2raG_pHPUnQFczqVmH68_BFT1SiKroYSGjfhFpXNJpwX6x3hEgjHMdqJuibP-XoMUwqk-bMQuVZZSSmr6Cb1nlkasvf_q6P3jNT0AOWeRTq6_79zeQD3gi_KFiN4HsIN1zyCO8ch2v4YmpXqSBOidWPHdVNfoPBX1w_Xt9jnMbLDVM8UO-2oE9J3hj4wW6JCJUWKUksCVfcBBVoEFL1ohQP5hVBni4va9hu23FZz6Z_A2dGXs-UqDvUZYpNlchN77TVub2QsVjshUq0M95QdJvFeCIeOhpEWyXqRpZZb7iT31mKDygqu0Hg-hYOmbdxzYKVWiUBpLpWfz7NMG2RaOkN2J9H_EyqC2XZ1KhNyl1MJje8Vchhaz-rv9Yzg_a7H5Zi34xrZT7TgOznKuD08aLvzKmzgSsmiTKVzhddm7oVURliZeZdzNCdpZiN4R3CpSC_g0IwK1xtwgpRhq1ogjRmCkDyCw4kkfn4zbd6Cpgr6pK_-ICaCN7tm6kln5BrXXg0yuBbE9yN4NuJzNyVRoF-a83kEcoLcyZynLU39bcg2nvAcLVFSvrh-XC_hbor-33jO8RAONt2VewW3zc9N3Xevh335GwbpQkw priority: 102 providerName: ProQuest
Title	Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
URI	https://www.ncbi.nlm.nih.gov/pubmed/37893604 https://www.proquest.com/docview/2882601412 https://www.proquest.com/docview/2883575499 https://pubmed.ncbi.nlm.nih.gov/PMC10608819 https://doaj.org/article/a87928ee7fbc4f38ac3d85fe6076225d
Volume	59
WOSCitedRecordID	wos001089806800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1648-9144 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032572 issn: 1648-9144 databaseCode: DOA dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1648-9144 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032572 issn: 1648-9144 databaseCode: 7X7 dateStart: 20180101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1648-9144 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032572 issn: 1648-9144 databaseCode: BENPR dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1648-9144 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032572 issn: 1648-9144 databaseCode: PIMPY dateStart: 20180101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwEB7BghAXxJvAUhkJCXGI6sRN4nDrll2VQ6totYdyivzURmJTlHQ58OuZSdKqAQkuXCqlHkex_XlmPs14DPDeRuhGRCYKXcQ1EpRUhtoYVIZSceNspLT03WUT2XotN5u8OLrqi3LC-vLA_cRNlczyWDqXeW1mXkhlhJWJdykScMSiJe3Ls3xPpnodLBCIfZwTtUya8k0foBRI8KdDzFolORWrojPURwapq9v_p3Y-Mk_j1MkjW3TxGB4NTiSb9x__BO64-ik8WA1h8mdQL1VDKgzNEltVdXWDwpeu7c5dsc99SIaplilWNNQJeTdD55UtUBOSBkSpBaGh-YQCW0QCvWi5baqfiFE2v6lsu2OL_TUs7XO4uji_WizD4WKF0CSJ3IVee437EqmG1U6IWCvDPZV1ibwXwqGHYKRFlp0lseWWO8m9tdigkowrtHov4KTe1u4VsFyrSKA0l8rPZkmiDVIknSAtk-i4CRXAdD-5pRmKjtPdF99KJB-0HOXvyxHAx0OP733Bjb_IntF6HeSoVHb3BwKoHABU_gtAAXyg1S5pQ-OnGTWcS8ABUmmsco78o4se8gBOR5I4_WbcvMdLOSiCtoyRwaSUTBsH8O7QTD0pua1229tOBteCiHoAL3t4HYYkMnQoUz4LQI6ANxrzuKWurrsy4Uj20YRE-ev_MUtv4GGM7l2fxngKJ7vm1r2F--bHrmqbCdzNNln3Kydw7-x8XVxOug2JT8WXVfH1F6V9OiQ
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9RADLZKQZQL70egwCCBEIdoJ5lNMkFCaNlSbdXuqkJ72Fs0mZnQlWhSki0I_hP_ETuPZQNSbz1wzXiiOLE_27HHBnhpPHQjPO251uMpBiihdFOtEQyl4toaT6Uyq4dNRLOZXCzi4y341Z2FobLKDhNroDaFpn_kAx9dwZCqEv33Z19dmhpF2dVuhEYjFof2x3cM2ap3B3v4fV_5_v7H-XjitlMFXB0EcuVmaZaiUKKfbVIrhJ8qzTPqaeJlmRAWzaOWBkPMKPANN9xKnhmDCyqIuELIx9tegasI4xHFetFiHd8JlP4muYrQFoZ80WRFhYj5oE2UqyCmDll0cHvDCtbDAv41CRs2sV-vuWEA92_9Z6_uNtxsPW02alTjDmzZ_C5cn7a1BPcgn6iScB5tN5su8-UpEn-yVX04je01eSumKqbYcUmbVkXJ0MNnYzQXZCaQakwqU75FggLVhW40Qb5_oiKz0enSVCs27mbVVPdhfhnMPoDtvMjtI2BxqjyB1FyqbDgMglRjHJkGGLtK9G6FcmDQCUOi287sNCDkS4IRGolP8rf4OPBmveOs6UpyAe0Hkq81HfUTry8U5eekhadEySj2pbVRluphJqTSwsggsyFHY-kHxoHXJJ0JoR4-mlbt4Q1kkPqHJSMM0uoUK3dgt0eJr1_3lzsZTVq0rJI_AurAi_Uy7aQKwNwW5zUNfgv6m-HAw0Yd1iyJCL3ukA8dkD1F6fHcX8mXJ3UvdY-HaGe9-PHFz_Ucdibz6VFydDA7fAI3fPR0m4rOXdhelef2KVzT31bLqnxWQwKD5JL16DfS8p_h
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9NADLaWLlpx4b0QWGCQQIhD1EmmSSZICJWWqtXSqkJ7KKdoMg-oxCZL0gXBP-Pf4cmjNCDtbQ9cM54oTmx_duyxAZ4pD90IT3qu9miKAUrI3VRKNIZcUKmVJ1JuqmET0WLBV6t4uQe_2rMwtqyytYmVoVa5tP_I-z66gqGtSvT7pimLWI4nb86-unaClM20tuM0ahE51j--Y_hWvp6N8Vs_9_3Ju5PR1G0mDLgyCPjGNalJUUDR51apZsxPhaTG9jfxjGFMI1RKrjDcjAJfUUU1p0YpXBBBRAWaf7ztFdhHj3zg92B_OZsvP7YwwFAX6lQrGrowpKs6R8pYTPtN2lwEse2XZY9x72BiNTrgX4DYQchu9eYOHE5u_Mcv8iZcb3xwMqyV5hbs6ew2HMybKoM7kE1FYREAUZ3M19n6FIk_6LI6tkbGdUaLiJIIsizspk1eEPT9yQiBxAIIUo2sMhWvkCBHRbI3miLfP1HFyfB0rcoNGbVTbMq7cHIZzB5CL8szfR9InAqPITXlwgwGQZBKjDDTAKNajn4vEw70W8FIZNOz3Y4O-ZJg7GZFKflblBx4ud1xVvcruYD2rZW1LZ3tNF5dyItPSWO4EsGj2OdaRyaVA8O4kEzxwOiQIoz6gXLghZXUxNpDfDQpmmMdyKDtLJYMMXyrkq_UgaMOJb5-2V1u5TVp7GiZ_BFWB55ul-1OWxuY6fy8osFvYf9zOHCvVo0tSyxCfzykAwd4R2k6PHdXsvXnqsu6R0NEYC9-cPFzPYEDVJ_k_Wxx_BCu-egC16WeR9DbFOf6EVyV3zbrsnjc2AcCySUr0m_i66ow
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Harnessing+Minimal+Residual+Disease+as+a+Predictor+for+Colorectal+Cancer%3A+Promising+Horizons+Amidst+Challenges&rft.jtitle=Medicina+%28Kaunas%2C+Lithuania%29&rft.au=Wen%2C+Xiaofen&rft.au=Coradduzza%2C+Donatella&rft.au=Shen%2C+Jiaxin&rft.au=Scanu%2C+Antonio+Mario&rft.date=2023-10-01&rft.eissn=1648-9144&rft.volume=59&rft.issue=10&rft_id=info:doi/10.3390%2Fmedicina59101886&rft_id=info%3Apmid%2F37893604&rft.externalDocID=37893604
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1648-9144&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1648-9144&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1648-9144&client=summon